Not provided
Not provided
Not provided
Not provided
Insufficient funding
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The investigators propose a randomized controlled superiority trial of standard breast-conserving surgery (BCS) versus BCS with cavity shave margins (CSM). The main objectives of this trial will be to evaluate prospectively the impact of routine standardized CSM on margin status following primary surgery for early stage breast cancer (Stage 0 - II), on post-operative patient satisfaction and cosmetic outcomes, and on general intraoperative time and operative costs. A parallel group format will be implemented to compare this modified surgical therapy - BCS with CSM - with BCS alone, which is the current standard of care.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| BCS Arm (breast-conserving surgery - standard of care) | Active Comparator |
|
|
| CSM Arm (breast-conserving surgery with cavity shave margins) | Experimental |
|
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Breast-conserving surgery (BCS) | Procedure |
|
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of patients with positive margins on pathological specimen analysis | Completion of surgery for all enrolled patients (approximately 60 months) | |
| Patient perceptions of the surgery as measured by BREAST-Q questionnaire and novel 3-dimensional breast imaging |
| 6-12 months post-surgery or post-radiation therapy, whichever is later) |
| Compare intraoperative NIR fluorescence from goggle system with pathologic tissue exam results | Completion of surgery for all enrolled patients (approximately 60 months) |
| Measure | Description | Time Frame |
|---|---|---|
| Relationship between CSM and volume of tissue excised in association iwth post-operative aesthetic outcomes | 6-12 months post-surgery or post-radiation therapy, whichever is later) | |
| Cost-effectiveness of routine CSM in BCS as measured by operative time, specimen processing, and resource usage |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Julie Margenthaler, M.D. | Washington University School of Medicine | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Washington University School of Medicine | St Louis | Missouri | 63110 | United States |
Not provided
| Label | URL |
|---|---|
| Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Cavity shave margins (CSM) | Procedure |
|
| BREAST-Q Questionnaire | Behavioral |
|
| 3-D breast imaging | Device | Using a 3-D breast imaging camera Vectra 3-D XT |
|
| Indocyanine green | Other |
|
|
| Intraoperative imaging device | Device | The goggle device is wearable, compact, and battery-operated, and it allows for hands-free operation by the wearer. The goggles provide functional information via a NIR light-emitting diode (LED) integrated within one of the eyepieces, which causes NIR fluorescence excitation of the molecular probes within the surgical field |
|
| Peripheral blood draw | Procedure | -Time of surgery if coordinator is available |
|
| Completion of surgery for all enrolled patients (approximately 60 months) |
| Disease status associated with cancer biomarkers | The investigators plan to assess plasma and serum levels of several candidate biomarkers, including a phosphorylated form of the annexin A2 protein ("P-annexin A2"), in study patients by immunoblotting/ELISA. This biomarker evaluation in the context of disease status will provide new information in the clinical detection and diagnosis of malignancy. Successful validation of these biomarkers may lead to development of novel blood-based cancer diagnostic tests. | Completion of surgery for all enrolled patients (approximately 60 months) |
| Tumor characteristics associated with cancer biomarkers | The investigators plan to assess plasma and serum levels of several candidate biomarkers, including a phosphorylated form of the annexin A2 protein ("P-annexin A2"), in study patients by immunoblotting/ELISA. This biomarker evaluation in the context of tumor characteristics will provide new information in the clinical detection and diagnosis of malignancy. Successful validation of these biomarkers may lead to development of novel blood-based cancer diagnostic tests. | Completion of surgery for all enrolled patients (approximately 60 months) |
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D015412 | Mastectomy, Segmental |
| D007208 | Indocyanine Green |
| ID | Term |
|---|---|
| D008408 | Mastectomy |
| D013514 | Surgical Procedures, Operative |
| D007211 | Indoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided